Navidea Biopharmaceuticals Inc Foglalás / Részvény
Mi az Navidea Biopharmaceuticals Inc Foglalás / Részvény?
A Foglalás / Részvény az Navidea Biopharmaceuticals Inc - -0.03
Mi a Foglalás / Részvény meghatározása?
Az egy részvényre jutó könyv szerinti érték egy vállalat eszköze, mínusz kötelezettségek, osztva a fennálló részvények számával.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Foglalás / Részvény a Health Care szektor a NYSEMKT-on cégekben a Navidea Biopharmaceuticals Inc -hoz képest
Mit csinál Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
foglalás / részvény -hoz hasonló cégek Navidea Biopharmaceuticals Inc
- FarmaForce nak Foglalás / Részvény -0.03 van
- Newtopia nak Foglalás / Részvény -0.03 van
- Curzon Plc nak Foglalás / Részvény -0.03 van
- Amarillo Biosciences nak Foglalás / Részvény -0.03 van
- Alkaline Water Inc nak Foglalás / Részvény -0.03 van
- Body & Mind nak Foglalás / Részvény -0.03 van
- Navidea Biopharmaceuticals Inc nak Foglalás / Részvény -0.03 van
- Lavide NV nak Foglalás / Részvény -0.03 van
- MedMira nak Foglalás / Részvény -0.03 van
- Thin Film Electronics ASA nak Foglalás / Részvény -0.03 van
- Jayex Healthcare nak Foglalás / Részvény -0.03 van
- Boomer nak Foglalás / Részvény -0.03 van
- Chilean Metals nak Foglalás / Részvény -0.03 van